Cannon Global Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Cannon Global Investment Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-7,800	Closed	-$681K	–	42
2024 Q1	$681K	Buy	7,800 +800	+11%	+$71.6K	1.83%	12
2023 Q4	$675K	Buy	+7,000	New	+$619K	5.07%	5
2023 Q3	–	Sell	-5,000	Closed	-$433K	–	30
2023 Q2	$433K	Buy	+5,000	New	+$471K	2.25%	17

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Cannon Global Investment Management's BMRN Position: Q2 2024 in Review

Cannon Global Investment Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2024, closing a stake of 7,800 shares — an estimated $681K sold.

Cannon Global Investment Management first reported a position in BMRN in Q2 2023 and held it in 3 quarters. The position peaked at $681K in Q1 2024. 559 funds tracked by Wall St. Rank hold BMRN as of Q2 2024.

Cannon Global Investment Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Cannon Global Investment Management sold 7,800 BioMarin Pharmaceuticals shares in Q2 2024, an estimated $681K.
Cannon Global Investment Management first reported a position in BioMarin Pharmaceuticals in Q2 2023 and held it in 3 quarters.
Cannon Global Investment Management's BioMarin Pharmaceuticals position peaked at $681K in Q1 2024.
559 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2024.

Based on Cannon Global Investment Management's 13F filing for Q2 2024, filed 2 Aug 2024.